Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHR | P35869 | 1/20 | 0.34 |
| ▸ | SETD7 | Q8WTS6 | 1/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.32 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.31 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.31 |
| ▸ | ESR1 | P03372 | 1/20 | 0.30 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3966628 | 0.85 | HSD17B1 (0.37) | SETD7PDK2 | |
| SCHEMBL3969110 | 0.85 | F10 (0.33) | SETD7PDK2 | |
| SCHEMBL3963936 | 0.84 | HDAC3 (0.32) | SETD7 | |
| SCHEMBL3961148 | 0.84 | BRD4 (0.33) | — | |
| SCHEMBL13617537 | 0.83 | SETD7 (0.32) | SETD7 | |
| SCHEMBL13617536 | 0.83 | SETD7 (0.32) | SETD7 | |
| SCHEMBL3379108 | 0.83 | SETD7 (0.32) | SETD7 | |
| SCHEMBL13627442 | 0.83 | SETD7 (0.31) | SETD7 | |
| SCHEMBL3963938 | 0.83 | SETD7 (0.31) | SETD7 | |
| SCHEMBL3961123 | 0.81 | CYP3A4 (0.35) | SETD7SLC6A2SLC6A4SLC6A3PDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090291979-A1 | TRICYCLIC-BRIDGED PIPERIDINYLIDENE DERIVATIVES AS DELTA OPIOID MODULATORS | DAX SCOTT | 2009-11-26 | — | — | US | disclosed |
| US-20090291979-A1 | TRICYCLIC-BRIDGED PIPERIDINYLIDENE DERIVATIVES AS DELTA OPIOID MODULATORS | DAX SCOTT | 2009-11-26 | — | — | US | disclosed |
| US-20090291979-A1 | TRICYCLIC-BRIDGED PIPERIDINYLIDENE DERIVATIVES AS DELTA OPIOID MODULATORS | DAX SCOTT | 2009-11-26 | — | — | US | disclosed |
| US-7589104-B2 | Tricyclic-bridged piperidinyline derivatives as §-opioid modulators | JANSSEN PHARMACEUTICA NV (BE) | 2009-09-15 | — | — | US | disclosed |
| US-7589104-B2 | Tricyclic-bridged piperidinyline derivatives as §-opioid modulators | JANSSEN PHARMACEUTICA NV (BE) | 2009-09-15 | — | — | US | disclosed |
| US-7553850-B2 | Tricyclic-bridged piperidinylidene derivatives as δ-opioid modulators | JANSSEN PHARMACEUTICA NV (BG) | 2009-06-30 | — | — | US | disclosed |
| US-7553850-B2 | Tricyclic-bridged piperidinylidene derivatives as δ-opioid modulators | JANSSEN PHARMACEUTICA NV (BG) | 2009-06-30 | — | — | US | disclosed |
| US-20060135524-A1 | Tricyclic delta-opioid modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-06-22 | — | — | US | disclosed |
| US-20060030585-A1 | Tricyclic delta-opioid modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135524-A1 | Tricyclic delta-opioid modulators | OPRD1, OPRK1, OPRL1 | AHR 853/4885SETD7 4197/4885SLC6A2 653/4885 |
| US-20090291979-A1 | TRICYCLIC-BRIDGED PIPERIDINYLIDENE DERIVATIVES AS DELTA OPIOID MODULATORS | OPRD1, OPRK1, OPRM1 | AHR 832/4885SETD7 3200/4885SLC6A2 2890/4885 |
| US-20060030585-A1 | Tricyclic delta-opioid modulators | OPRD1, OPRK1, OPRL1 | AHR 853/4885SETD7 4197/4885SLC6A2 653/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.